Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1959 1
1961 2
1962 2
1963 3
1964 2
1965 2
1966 3
1967 9
1968 1
1969 3
1970 5
1971 4
1972 5
1973 7
1974 16
1975 19
1976 12
1977 20
1978 14
1979 18
1980 25
1981 14
1982 22
1983 19
1984 34
1985 36
1986 26
1987 35
1988 33
1989 50
1990 49
1991 34
1992 40
1993 34
1994 46
1995 46
1996 38
1997 45
1998 63
1999 59
2000 62
2001 79
2002 94
2003 93
2004 120
2005 89
2006 83
2007 83
2008 94
2009 75
2010 97
2011 114
2012 116
2013 146
2014 182
2015 180
2016 226
2017 233
2018 244
2019 259
2020 273
2021 301
2022 293
2023 256
2024 121

Text availability

Article attribute

Article type

Publication date

Search Results

4,338 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Colombo N, et al. Among authors: hasegawa k. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. N Engl J Med. 2021. PMID: 34534429 Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: hasegawa k. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022.
Joliat GR, Kobayashi K, Hasegawa K, Thomson JE, Padbury R, Scott M, Brustia R, Scatton O, Tran Cao HS, Vauthey JN, Dincler S, Clavien PA, Wigmore SJ, Demartines N, Melloul E. Joliat GR, et al. Among authors: hasegawa k. World J Surg. 2023 Jan;47(1):11-34. doi: 10.1007/s00268-022-06732-5. Epub 2022 Oct 30. World J Surg. 2023. PMID: 36310325 Free PMC article. Review.
Advances in the surgical treatment of liver cancer.
Maki H, Hasegawa K. Maki H, et al. Among authors: hasegawa k. Biosci Trends. 2022 Jul 20;16(3):178-188. doi: 10.5582/bst.2022.01245. Epub 2022 Jun 23. Biosci Trends. 2022. PMID: 35732434 Free article. Review.
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D; KEYNOTE-826 Investigators. Monk BJ, et al. Among authors: hasegawa k. J Clin Oncol. 2023 Dec 20;41(36):5505-5511. doi: 10.1200/JCO.23.00914. Epub 2023 Nov 1. J Clin Oncol. 2023. PMID: 37910822
Structures of α-synuclein filaments from human brains with Lewy pathology.
Yang Y, Shi Y, Schweighauser M, Zhang X, Kotecha A, Murzin AG, Garringer HJ, Cullinane PW, Saito Y, Foroud T, Warner TT, Hasegawa K, Vidal R, Murayama S, Revesz T, Ghetti B, Hasegawa M, Lashley T, Scheres SHW, Goedert M. Yang Y, et al. Among authors: hasegawa k. Nature. 2022 Oct;610(7933):791-795. doi: 10.1038/s41586-022-05319-3. Epub 2022 Sep 15. Nature. 2022. PMID: 36108674 Free PMC article.
Age-dependent formation of TMEM106B amyloid filaments in human brains.
Schweighauser M, Arseni D, Bacioglu M, Huang M, Lövestam S, Shi Y, Yang Y, Zhang W, Kotecha A, Garringer HJ, Vidal R, Hallinan GI, Newell KL, Tarutani A, Murayama S, Miyazaki M, Saito Y, Yoshida M, Hasegawa K, Lashley T, Revesz T, Kovacs GG, van Swieten J, Takao M, Hasegawa M, Ghetti B, Spillantini MG, Ryskeldi-Falcon B, Murzin AG, Goedert M, Scheres SHW. Schweighauser M, et al. Among authors: hasegawa k. Nature. 2022 May;605(7909):310-314. doi: 10.1038/s41586-022-04650-z. Epub 2022 Mar 28. Nature. 2022. PMID: 35344985 Free PMC article.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: hasegawa k. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Toward Precision Epidemiology in Bronchiolitis.
Makrinioti H, Camargo CA Jr, Jartti T, Hasegawa K. Makrinioti H, et al. Among authors: hasegawa k. Chest. 2022 Oct;162(4):744-746. doi: 10.1016/j.chest.2022.06.003. Epub 2022 Jun 10. Chest. 2022. PMID: 35697121 No abstract available.
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orlowski R, Miura T, Makker V, Fujiwara K. Yonemori K, et al. Among authors: hasegawa k. Cancer Sci. 2022 Oct;113(10):3489-3497. doi: 10.1111/cas.15436. Epub 2022 Jul 26. Cancer Sci. 2022. PMID: 35612971 Free PMC article. Clinical Trial.
4,338 results